Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis
about
Feedback amplification of fibrosis through matrix stiffening and COX-2 suppressionMulti-walled carbon nanotubes induce COX-2 and iNOS expression via MAP kinase-dependent and -independent mechanisms in mouse RAW264.7 macrophagesMechanisms of action of inhaled fibers, particles and nanoparticles in lung and cardiovascular diseasesSuppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105Genomic analysis of human lung fibroblasts exposed to vanadium pentoxide to identify candidate genes for occupational bronchitisRespiratory syncytial virus infection reduces lung inflammation and fibrosis in mice exposed to vanadium pentoxide.Vanadium pentoxide induces pulmonary inflammation and tumor promotion in a strain-dependent manner.Retrovirally introduced prostaglandin D2 synthase suppresses lung injury induced by bleomycin.Lung myofibroblasts are characterized by down-regulated cyclooxygenase-2 and its main metabolite, prostaglandin E2.Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury.Novel biphasic role of LipoxinA(4) on expression of cyclooxygenase-2 in lipopolysaccharide-stimulated lung fibroblasts.Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production.Effect of a single nucleotide polymorphism in miR-146a on COX-2 protein expression and lung function in smokers with chronic obstructive pulmonary disease.Translational research: current status, challenges and future strategies.Prostaglandin E₂ protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction.Prostaglandin Transporter (PGT/SLCO2A1) Protects the Lung from Bleomycin-Induced Fibrosis.Cytosolic phospholipase A₂: physiological function and role in disease.Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosisCytosolic phospholipase A2 contributes to innate immune defense against Candida albicans lung infectionIs COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial.Lipopolysaccharide-induced cyclooxygenase-2 expression in mouse transformed Clara cellsThe role of cyclooxygenase-2 in mechanical ventilation-induced lung injury.Contribution of alveolar type II cell-derived cyclooxygenase-2 to basal airway function, lung inflammation, and lung fibrosis.Cyclooxygenase-1 overexpression decreases Basal airway responsiveness but not allergic inflammation.Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injuryEpigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosisUsing mouse genomics to understand idiopathic interstitial fibrosis.Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences.Regulation of myofibroblast differentiation by cardiac glycosidesAdvances in mechanisms of repair and remodelling in acute lung injury.Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membraneEvaluation of the Effects of Caffeic Acid Phenethyl Ester on Prostaglandin E2 and Two Key Cytokines Involved in Bleomycin-induced Pulmonary FibrosisNovel biphasic role of resolvin D1 on expression of cyclooxygenase-2 in lipopolysaccharide-stimulated lung fibroblasts is partly through PI3K/AKT and ERK2 pathways.Protease-activated receptors and prostaglandins in inflammatory lung disease.Antifibrotic effects of noscapine through activation of prostaglandin E2 receptors and protein kinase A.A review of current toxicological concerns on vanadium pentoxide and other vanadium compounds: gaps in knowledge and directions for future research.COX inhibitors for airway inflammation.Regulation of transforming growth factor-beta-dependent cyclooxygenase-2 expression in fibroblasts.COX-2 expression induced by diesel particles involves chromatin modification and degradation of HDAC1.Expression of secretory phospholipase A2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells.
P2860
Q24627446-71A84D9B-CEA4-4039-B083-E942D996BF64Q28390379-EFE69027-DF8B-4F82-A5B3-E2722C9CD057Q28396026-2840DB7B-4B51-404E-B1FA-6994E3ECCE7AQ28513770-734A2EC3-676E-49F3-885C-288C19B118DAQ28757798-9FDF6537-1DBE-4181-B3C6-504DE695F683Q33738914-FEB9177B-6F50-4075-A3FC-272273D888D0Q33816019-F45F7AA7-89C1-49BD-928B-666D87186E0DQ34191947-1B29C034-155D-4630-A154-1C8C1747CB03Q34766530-AA8F9563-0AB4-47CA-8B09-A97F9B558891Q35088140-0CA57B8E-E01F-49A7-9349-C6B1666DA2F3Q35099252-87B1F133-B40D-478B-9F06-FDE844B3F3B9Q35103340-EA5335F1-D2A1-4588-9CFB-406889C16773Q35161579-F865B7B0-E51A-486B-B855-87B3B93E9A8AQ35485519-D84FE359-2420-41A0-B0E4-22096CBA8917Q35543612-415517DD-1703-437B-A4E2-F5F29725355AQ35617407-CAD9AC17-690C-4DD2-B279-F847AAEC2A1DQ35886245-6DE2E0F7-B8A0-44F6-AC4F-602739E1915AQ36013692-C3561660-24C9-4C3A-B656-DD624B14DDA7Q36097784-36FB9788-4127-4352-B7D7-0E59C1DE4438Q36204500-DC60E6C6-5C92-4EF5-ADE5-CA925B44C9E7Q36365725-D7C9D7E8-6A08-43F3-BF56-8385D4830C5EQ36370165-50A2D5EC-3021-4FEB-9AE6-4624F2D22E36Q36385368-96EA74EE-C296-492B-BCB6-B44E08492FF9Q36420377-8373CF55-D66B-49B1-AFF8-29779AAF90EBQ36661617-846E4076-F6AB-46B4-B12C-2825311E0BCDQ36661876-B35E8A61-E060-410A-BF4D-BD1C6B54A1C9Q36698831-162D990E-AB40-495B-93AD-E1A9B050653CQ36773491-CDE19E97-DBF7-4008-B71A-6EAF8FE0683CQ36902368-058D8B9B-FD9F-41CA-9F90-A075DC0D7FA4Q37081002-0CF68416-7586-4736-81EE-93E92F6B213FQ37123283-AD9845F6-B550-4E7A-98E4-818BED20B5C2Q37134327-910ABDB0-F521-479D-89CA-C545ACCA86A4Q37224692-26595906-B832-4F8E-9DE5-8BBDA3A19E6DQ37447476-04F2E211-6903-4718-8A72-F11F7BA4E720Q37635787-1B8F5CE8-C21E-42E1-BF06-90D326388A5EQ37698401-23A19E78-955C-4C35-96C6-C4FBCDA340D5Q37983125-E49297BE-15F5-4E5D-97F9-D0530FFE1A8BQ39786360-4427D710-9830-4039-80FA-BC81A5E0635BQ40152021-52C63B28-D518-44BB-9E5F-D821AB2C906BQ40499280-75F89A79-68AB-4B92-AE76-40C6F17F3EF6
P2860
Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis
@ast
Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis
@en
type
label
Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis
@ast
Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis
@en
prefLabel
Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis
@ast
Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis
@en
P2093
P2860
P1476
Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis
@en
P2093
Abraham Nyska
Alisha R Sessoms
Alyce Bradbury
Annette B Rice
Cindy R Moomaw
Daniel L Morgan
James C Bonner
Jennifer L Ingram
Patricia C Chulada
Robert Langenbach
P2860
P304
P356
10.1016/S0002-9440(10)64202-2
P407
P577
2002-08-01T00:00:00Z